Gold(III) porphyrin 1a prolongs the survival of melanoma-bearing mice and inhibits angiogenesis

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.
   PubMed Web of Science ®Google Scholar
• Bellett RE, Mastrangelo MJ, Laucius JF, Bodurtha AJ. Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma. Cancer Treat Rep 1976;60:595–600.
   Google Scholar
• Cagnoli M, Alama A, Barbieri F, Novelli F, Bruzzo C, Sparatore F. Synthesis and biological activity of gold and tin compounds in ovarian cancer cells. Anticancer Drugs 1998;9:603–10.
   Google Scholar
• Marcon G, Carotti S, Coronnello M, Messori L, Mini E, Orioli P, . Gold(III) complexes with bipyridyl ligands: Solution chemistry, cytotoxicity, and DNA binding properties. J Med Chem 2002;45:1672–7.
   PubMed Web of Science ®Google Scholar
• Ward JR. Role of disease-modifying antirheumatic drugs versus cytotoxic agents in the therapy of rheumatoid arthritis. Am J Med 1988;85:39–44.
   PubMedGoogle Scholar
• Simon TM, Kunishima DH, Vibert GJ, Lorber A. Cellular antiproliferative action exerted by auranofin. J Rheumatol Suppl 1979;5:91–7.
   Google Scholar
• Simon TM, Kunishima DH, Vibert GJ, Lorber A. Inhibitory effects of a new oral gold compound on HeLa cells. Cancer 1979;44:1965.
   PubMed Web of Science ®Google Scholar
• Tiekink ER. Gold derivatives for the treatment of cancer. Crit Rev Oncol Hematol 2002;42:225–48.
   PubMed Web of Science ®Google Scholar
• Sun RW, Che CM. The anti-cancer properties of gold(III) compounds with dianionic porphyrin and tetradentate ligands. Coord Chem Rev 2009;253:1682–91.
   Web of Science ®Google Scholar
• Lum CT, Yang ZF, Li HY, Sun RW, Fan ST, Poon RT, . Gold(III) compound is a novel chemo-cytotoxic agent for hepatocellular carcinoma (HCC). Int J Cancer 2006;118:1527–38.
   PubMed Web of Science ®Google Scholar
• Lum CT, Liu X, Sun RW, Li XP, Peng Y, He ML, . Gold(III) porphyrin 1a inhibited nasopharyngeal carcinoma metastasis in vivo and inhibited cell migration and invasion in vitro. Cancer Lett 2010;294:159–66.
   Google Scholar
• To YF, Sun RW, Chen Y, Chan VS, Yu WY, Tam PK, . Gold(III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo. Int J Cancer 2009;124:1971–9.
   PubMed Web of Science ®Google Scholar
• Li W, Xie Y, Sun RW, Liu Q, Young J, Yu WY, . Inhibition of Akt sensitizes neuroblastoma cells to gold(III) porphyrin 1a, a novel antitumour drug induced apoptosis and growth inhibition. Br J Cancer 2009;101:342–9.
   Web of Science ®Google Scholar
• Tu S, Sun RW, Lin MC, Cui JT, Zou B, Gu Q, . Gold(III) porphyrin complexes induce apoptosis and cell cycle arrest and inhibit tumor growth in colon cancer. Cancer 2009; 115:4459–69.
   Google Scholar
• Wang Y, He QY, Sun RW, Che CM, Chiu JF. GoldIII porphyrin 1a induced apoptosis by mitochondrial death pathways related to reactive oxygen species. Cancer Res 2005;65:11553–64.
   Google Scholar
• Nyberg P, Salo T, Kalluri R. Tumor microenvironment and angiogenesis. Front Biosci 2008;13:6537–53.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407(6801):249–57.
   PubMed Web of Science ®Google Scholar
• Che CM, Sun RW, Yu WY, Ko CB, Zhu N, Sun H. Gold(III) porphyrins as a new class of anticancer drugs: Cytotoxicity, DNA binding and induction of apoptosis in human cervix epitheloid cancer cells. Chem Commun (Camb) 2003;14:1718–9.
   Web of Science ®Google Scholar
• Lens MB, Eisen TG. Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin Pharmacother 2003;4:2205–11.
   PubMed Web of Science ®Google Scholar
• Kahn J, Mehraban F, Ingle G, Xin X, Bryant JE, Vehar G, . Gene expression profiling in an in vitro model of angiogenesis. Am J Pathol 2000;156:1887–900.
   PubMed Web of Science ®Google Scholar
• Zlot C, Ingle G, Hongo J, Yang S, Sheng Z, Schwall R, . Stanniocalcin 1 is an autocrine modulator of endothelial angiogenic responses to hepatocyte growth factor. J Biol Chem 2003;278:47654–9.
   PubMed Web of Science ®Google Scholar
• Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006;39:469–78.
   PubMedGoogle Scholar
• Sun RW, Ma DL, Wong EL, Che CM. Some uses of transition metal complexes as anti-cancer and anti-HIV agents. Dalton Trans 2007;43:4884–92.
   PubMed Web of Science ®Google Scholar
• Sun RW, Che CM. The anti-cancer properties of gold(III) compounds with dianionic porphyrin and tetradentate ligands. Coord Chem Rev 2009;253:1682–91.
   Web of Science ®Google Scholar
• Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, . Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62–6.
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Koukourakis MI, Sivridis E, Chlouverakis G, Vourvouhaki E, Turley H, . Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Eur J Clin Invest 2007;37:878–86.
   PubMed Web of Science ®Google Scholar